Attention Deficit Hyperactivity Disorder (ADHD) medication shortage
ADHD Medicine Shortages September 2024
With the ongoing supply issues relating to ADHD medicines a summary position has been produced by the ICB and Health and Care Trust Pharmacy Teams Advice for ADHD Medicine Shortages September 2024
Key points are:
- Patients on regular repeats and stable doses are advised to continue with current prescription.
- No new patients to be initiated on prolonged release methylphenidate, unless absolutely necessary based on clinical judgement of team/ specialist.
- For paediatric patients the HW Health and Care Trust community paediatricians:
• Advise not to switch medication to alternative formulations including those with the same bioavailability. This is to avoid confusion and ensure a safe process with the ever-changing landscape of what is in stock and risk of multiple switches and confusion for patients/ carers.
• Support patients taking treatment break(s) where appropriate and necessary if medication is not available.
• Advise to continue to prescribe medication by brand.
• Are unable to respond to patients or GPs about changing medication due to stock availability except where advice is needed for guanfacine which cannot be stopped abruptly because of risk of rebound hypertension or atomoxetine where locally the advice is that stopping suddenly may produce a withdrawal reaction and a gradual withdrawal is preferable.
Advice for parents is available on the Health and Care Trust website: I think my child might have ADHD | Herefordshire and Worcestershire Health and Care NHS Trust (hacw.nhs.uk)